BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cobicistat: Phase III data

The 96-week, double-blind, international Phase III Study 114 trial in 692 treatment-naive patients with HIV RNA levels >=5,000 copies/mL showed that cobicistat-boosted atazanavir plus Truvada emtricitabine/tenofovir met the primary endpoint of non-inferiority to ritonavir-boosted atazanavir plus Truvada in the proportion of patients who achieved HIV RNA levels <50 copies/mL at week 48 (85% vs....

Read the full 259 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >